The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM).
 
Eric Leon Tam
Stock and Other Ownership Interests - Celgene
 
David Joseph Iberri
No Relationships to Disclose
 
Michaela Liedtke
Honoraria - Amgen
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; Caelum Biosciences; Gilead Sciences; IQvia; Janssen; Prothena; Takeda
Research Funding - Agios (Inst); Amgen (Inst); Bluebird Bio (Inst); Celator/Jazz (Inst); Celgene (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Janssen (Inst); Pfizer (Inst); Prothena (Inst); Takeda (Inst)
 
Lori S. Muffly
Stock and Other Ownership Interests - Corvus Pharmaceuticals
Consulting or Advisory Role - Amgen; Kite, a Gilead company; Pfizer
Research Funding - Adaptive Biotechnologies; Astellas Pharma; Shire
 
Parveen Shiraz
No Relationships to Disclose
 
Matthew Joshua Frank
No Relationships to Disclose
 
Robert Lowsky
No Relationships to Disclose
 
Andrew Rezvani
Consulting or Advisory Role - Kaleido Biosciences; Nohla Therapeutics
Research Funding - Pharmacyclics
 
Robert Negrin
No Relationships to Disclose
 
Everett Meyer
No Relationships to Disclose
 
Sally Arai
No Relationships to Disclose
 
Laura J. Johnston
No Relationships to Disclose
 
Judith Shizuru
No Relationships to Disclose
 
Wen-Kai Weng
No Relationships to Disclose
 
David Bernard Miklos
Consulting or Advisory Role - Adaptive Biotechnologies; Alimera Sciences; Janssen; Juno/Celgene; Kite, a Gilead company; Miltenyi Biotec; Novartis; Pharmacyclics; Precision Biosciences
Research Funding - Adaptive Biotechnologies; Alimera Sciences; Kite, a Gilead company; Novartis; Novartis; Pharmacyclics; Precision Biosciences; Roche/Genentech
Patents, Royalties, Other Intellectual Property - Patent held with Pharmacyclics supporting Ibrutinib for cGVHD (no royalty claim)
Travel, Accommodations, Expenses - Adaptive Biotechnologies; Juno Therapeutics; Kite, a Gilead company; Miltenyi Biotec; Novartis; Pharmacyclics/Janssen
 
Surbhi Sidana
Consulting or Advisory Role - Janssen